Kopran Limited
NSE: KOPRAN BSE: KOPRAN
Prev Close
160.95
Open Price
160.88
Volume
65,340
Today Low / High
158.7 / 161.88
52 WK Low / High
155 / 369.7
Range
151 - 167
Prev Close
160.9
Open Price
160.9
Volume
2,008
Today Low / High
159 / 161.9
52 WK Low / High
156.5 / 369.2
Range
151 - 167
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 159.36 (target range: 151 - 167), reflecting a change of -1.59 (-0.98788%). On the BSE, it is listed at 159 (target range: 151 - 167), showing a change of -1.9 (-1.18086%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Kopran Limited Graph
Kopran Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Kopran Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 159.36, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 159.00 | 160.59 | 144.53 - 176.65 |
| 162.18 | 129.74 - 194.62 | ||
| 163.77 | 114.64 - 212.90 | ||
| Bearish Scenario | 159.00 | 157.41 | 141.67 - 173.15 |
| 155.82 | 124.66 - 186.98 | ||
| 154.23 | 107.96 - 200.50 |
Overview of Kopran Limited
ISIN
INE082A01010
Industry
Drug Manufacturers - General
Vol.Avg
235,733
Market Cap
7,694,793,216
Last Dividend
3
Official Website
IPO Date
2002-07-01
DCF Diff
400.29
DCF
-199
Financial Ratios Every Investor Needs
Stock Dividend of KOPRAN
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-04 | September 04, 25 | 3 | 3 | 2025-09-04 | 2025-10-11 | |
| 2024-09-02 | September 02, 24 | 3 | 3 | 2024-09-02 | 2024-10-11 | |
| 2023-09-07 | September 07, 23 | 3 | 3 | 2023-09-07 | 2023-10-14 | |
| 2022-08-04 | August 04, 22 | 3 | 3 | 2022-08-06 | 2022-09-28 | |
| 2021-08-05 | August 05, 21 | 1.5 | 1.5 | 2021-08-07 | 2021-09-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 629.60 Cr | 404.62 Cr | 224.99 Cr | 0.3573 | 0.00 Cr | 0.00 Cr | 164.45 Cr | 38.55 Cr | 7.99 | 72.90 Cr | 0.0612 |
| 2024-03-31 | 610.09 Cr | 405.47 Cr | 204.62 Cr | 0.3354 | 0.00 Cr | 10.46 Cr | 67.54 Cr | 50.96 Cr | 10.57 | 86.82 Cr | 0.0835 |
| 2023-03-31 | 548.18 Cr | 361.72 Cr | 186.46 Cr | 0.3402 | 0.00 Cr | 9.15 Cr | 45.28 Cr | 27.23 Cr | 5.65 | 54.88 Cr | 0.0497 |
| 2022-03-31 | 474.28 Cr | 284.11 Cr | 190.17 Cr | 0.4010 | 0.66 Cr | 8.55 Cr | 76.76 Cr | 61.03 Cr | 13.77 | 98.01 Cr | 0.1287 |
| 2021-03-31 | 481.49 Cr | 314.30 Cr | 167.19 Cr | 0.3472 | 0.00 Cr | 8.56 Cr | 73.31 Cr | 61.61 Cr | 14.24 | 99.78 Cr | 0.1280 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 25.86 Cr | 844.01 Cr | 325.66 Cr | 518.3479 Cr | 147.79 Cr | 121.92 Cr | 169.42 Cr | 296.03 Cr | 0.00 Cr | 0.00 Cr | 0.06 Cr | 288.9674 Cr |
| 2024-03-31 | 8.09 Cr | 743.25 Cr | 252.00 Cr | 491.2450 Cr | 99.23 Cr | 91.14 Cr | 138.49 Cr | 256.69 Cr | 1.07 Cr | 0.00 Cr | 0.00 Cr | 218.5299 Cr |
| 2023-03-31 | 7.40 Cr | 649.70 Cr | 210.45 Cr | 439.2457 Cr | 75.24 Cr | 67.84 Cr | 130.61 Cr | 227.23 Cr | 1.81 Cr | 0.00 Cr | 0.00 Cr | 176.9710 Cr |
| 2022-03-31 | 5.87 Cr | 610.89 Cr | 184.72 Cr | 426.1689 Cr | 74.55 Cr | 68.68 Cr | 149.94 Cr | 179.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 151.5856 Cr |
| 2021-03-31 | 0.94 Cr | 439.38 Cr | 194.35 Cr | 245.0304 Cr | 66.30 Cr | 65.37 Cr | 100.00 Cr | 148.41 Cr | 2.38 Cr | 0.00 Cr | 0.00 Cr | 160.6843 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 41.9421 Cr | -56.4280 Cr | 25.8675 Cr | -13.4460 Cr | 11.3816 Cr | 19.4728 Cr | -55.3881 Cr | 38.5519 Cr | 48.4013 Cr | -14.4632 Cr | -30.2256 Cr |
| 2024-03-31 | 43.2582 Cr | -43.5521 Cr | 0.9885 Cr | -13.3565 Cr | 0.6946 Cr | 8.0912 Cr | -50.4396 Cr | 50.9561 Cr | 23.9905 Cr | -14.4632 Cr | -7.8727 Cr |
| 2023-03-31 | 34.0229 Cr | -12.6504 Cr | -19.8442 Cr | -27.0224 Cr | 1.5283 Cr | 7.3966 Cr | -54.8958 Cr | 36.0659 Cr | -0.8937 Cr | -14.4632 Cr | 19.3260 Cr |
| 2022-03-31 | -33.4751 Cr | -84.4153 Cr | 122.8234 Cr | -75.7470 Cr | 4.9330 Cr | 5.8683 Cr | -39.7523 Cr | 81.7808 Cr | 8.3283 Cr | -6.4876 Cr | -49.9360 Cr |
| 2021-03-31 | 59.9513 Cr | -25.2792 Cr | -34.5713 Cr | 35.5372 Cr | 0.1008 Cr | 0.9353 Cr | -24.5020 Cr | 83.3360 Cr | -8.4790 Cr | -6.4877 Cr | -11.5070 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 135.22 Cr | 85.40 Cr | 49.81 Cr | 0.3684 | 9.87 Cr | 7.45 Cr | 1.54 | 16.69 Cr | 0.0551 |
| 2025-03-31 | 172.36 Cr | 115.36 Cr | 57.00 Cr | 0.3307 | 39.74 Cr | 9.68 Cr | 2.01 | 17.12 Cr | 0.0561 |
| 2024-12-31 | 166.24 Cr | 105.70 Cr | 60.54 Cr | 0.3642 | 18.91 Cr | 10.40 Cr | 2.16 | 20.01 Cr | 0.0625 |
| 2024-09-30 | 151.56 Cr | 97.65 Cr | 53.91 Cr | 0.3557 | 10.88 Cr | 7.38 Cr | 1.53 | 15.73 Cr | 0.0487 |
| 2024-06-30 | 139.44 Cr | 85.90 Cr | 53.54 Cr | 0.3839 | 14.29 Cr | 11.10 Cr | 2.30 | 20.79 Cr | 0.0796 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 25.86 Cr | 0.00 Cr | 25.86 Cr | 214.93 Cr | 169.42 Cr | 509.75 Cr | 296.03 Cr | 844.01 Cr | 325.66 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 8.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -497.31 Cr |
| 2024-09-30 | 1.88 Cr | 6.54 Cr | 8.42 Cr | 180.67 Cr | 161.15 Cr | 434.31 Cr | 273.50 Cr | 747.46 Cr | 250.15 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 14.20 Cr | 0.00 Cr | 0.00 Cr | 14.20 Cr | 0.00 Cr | 0.00 Cr | -491.25 Cr |
| 2024-03-31 | 8.09 Cr | 6.11 Cr | 14.20 Cr | 212.33 Cr | 138.49 Cr | 454.03 Cr | 256.69 Cr | 743.25 Cr | 252.00 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 9.68 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 10.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 7.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 11.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 18.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - General
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Cipla Limited | CIPLA | ₹1,592.80 | ₹1,286,590,545,715.00 | ₹1,574,525.00 |
| Abbott India Limited | ABBOTINDIA | ₹31,875.00 | ₹677,321,437,500.00 | ₹6,991.00 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹2,798.80 | ₹474,133,512,800.00 | ₹39,428.00 |
| Gland Pharma Limited | GLAND | ₹1,957.40 | ₹322,493,394,400.00 | ₹430,192.00 |
| Pfizer Limited | PFIZER | ₹5,668.50 | ₹259,320,837,450.00 | ₹24,713.00 |
| Sanofi India Limited | SANOFI | ₹5,230.50 | ₹120,458,415,000.00 | ₹7,436.00 |
| Marksans Pharma Limited | MARKSANS | ₹179.96 | ₹81,551,393,440.00 | ₹681,593.00 |
Key Executives
Gender: male
Year Born:
Gender: female
Year Born:
Gender: male
Year Born: 1954
Gender: male
Year Born: 1961
Gender: male
Year Born:
FAQs about Kopran Limited
The CEO is Surendra Shrikrishna Somani.
The current price is ₹159.36.
The range is ₹155-369.7.
The market capitalization is ₹769.48 crores.
The dividend yield is 1.88%.
The P/E ratio is 22.08.
The company operates in the Healthcare sector.
Overview of Kopran Limited (ISIN: INE082A01010) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹769.48 crores and an average daily volume of 235,733 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹3.